.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Drug patents in 130+ countries
  • Set up watchlists for daily email updates

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Fish and Richardson
Argus Health
Mallinckrodt
McKinsey
AstraZeneca
Accenture
QuintilesIMS
Express Scripts
Merck
Queensland Health

Generated: July 22, 2017

DrugPatentWatch Database Preview

Delavirdine mesylate - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for delavirdine mesylate and what is the scope of delavirdine mesylate freedom to operate?

Delavirdine mesylate
is the generic ingredient in one branded drug marketed by Viiv Hlthcare and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Delavirdine mesylate has twenty-two patent family members in twenty countries.

Two suppliers are listed for this compound.

Summary for Generic Name: delavirdine mesylate

Tradenames:1
Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list21
Clinical Trials: see list525
Patent Applications: see list3,207
Therapeutic Class:Antivirals
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:delavirdine mesylate at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare
RESCRIPTOR
delavirdine mesylate
TABLET;ORAL020705-002Jul 14, 1999RXYesYes6,177,101► Subscribe ► Subscribe
Viiv Hlthcare
RESCRIPTOR
delavirdine mesylate
TABLET;ORAL020705-001Apr 4, 1997RXYesNo► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: delavirdine mesylate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viiv Hlthcare
RESCRIPTOR
delavirdine mesylate
TABLET;ORAL020705-001Apr 4, 19975,563,142► Subscribe
Viiv Hlthcare
RESCRIPTOR
delavirdine mesylate
TABLET;ORAL020705-002Jul 14, 19995,563,142► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: delavirdine mesylate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,108,864Tablet formation► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: delavirdine mesylate

Country Document Number Estimated Expiration
Japan2002517430► Subscribe
Australia4213499► Subscribe
Austria349203► Subscribe
Canada2328703► Subscribe
European Patent Office1083885► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Daiichi Sankyo
McKesson
Harvard Business School
Covington
US Department of Justice
Accenture
Merck
Express Scripts
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot